The Celsion Corp. Forecasted to Post FY2021 Earnings of $0.27 Per Share (CLSN)

The Celsion Corp. Forecasted to Post FY2021 Earnings of $0.27 Per Share (CLSN)

Celsion Corp. (NASDAQ:CLSN) – Equities research analysts at Griffin Securities issued their FY2021 EPS estimates for Celsion Corp. in a report released on Tuesday. Griffin Securities analyst K. Markey expects that the firm will post earnings of $0.27 per share for the year.

Other equities analysts have also issued reports about the company. Zacks Investment Research upgraded Celsion Corp. from a “sell” rating to a “buy” rating and set a $0.50 price objective on the stock in a research note on Friday. HC Wainwright reiterated a “buy” rating on shares of Celsion Corp. in a research note on Monday, November 14th. Finally, Maxim Group lowered Celsion Corp. from a “buy” rating to a “hold” rating in a research note on Thursday, November 10th.

Celsion Corp. (NASDAQ:CLSN) traded down 3.94% during mid-day trading on Thursday, reaching $0.39. The company had a trading volume of 778,306 shares. Celsion Corp. has a 52-week low of $0.29 and a 52-week high of $1.78. The stock’s market capitalization is $10.17 million. The company’s 50 day moving average is $0.45 and its 200 day moving average is $0.98.

An institutional investor recently bought a new position in Celsion Corp. stock. Seizert Capital Partners LLC purchased a new stake in shares of Celsion Corp. (NASDAQ:CLSN) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 120,022 shares of the company’s stock, valued at approximately $152,000. Seizert Capital Partners LLC owned 0.51% of Celsion Corp. as of its most recent filing with the SEC. 10.75% of the stock is currently owned by hedge funds and other institutional investors.

Celsion Corp. Company Profile

Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).

Related posts

Leave a Comment